论文部分内容阅读
为研究慢性髓性白血病 (CML)异基因造血干细胞移植 (SCT)后M bcr/abl及m bcr/abl融合转录子表达特征 ,采用逆转录 聚合酶链反应 (RT PCR)技术测定 72例CML患者SCT后不同时间骨髓M bcr/abl及m bcr/abl融合转录子的表达。结果显示 ,CML患者移植后 <6个月M bcr/abl阳性率 (79.2 % ,4 2 /5 3)显著高于 6 - 12个月(34.3% ,11/32 )及≥ 12个月 (35 .1% ,13/37) (P <0 .0 0 1) ,各时间段M bcr/abl阳性患者的临床复发率分别为1 9% (1/5 3) ,0 (0 /32 )及 16 .2 % (6 /37) ;6例临床复发患者中有 5例复发时M bcr/abl与m bcr/abl同时阳性。 14例遗传学缓解患者移植 6个月后M bcr/abl阳性的 17份标本无 1例m bcr/abl阳性。结论 :多数CML患者移植后M bcr/abl仍为阳性 ,一般在 6个月内转阴 ,移植后M bcr/abl阳性的患者不一定复发 ,同时追踪观察M bcr/abl及m bcr/abl融合转录子可能会有助于监测残存白血病。
In order to study the expression characteristics of M bcr / abl and m bcr / abl fusion transcripts after chronic myeloid leukemia (CML) allogeneic hematopoietic stem cell transplantation (SCT), RT-PCR was used to detect 72 CML patients The expression of M bcr / abl and m bcr / abl fusion transcripts in bone marrow at different time after SCT. The results showed that the positive rate of M bcr / abl at 6 months after transplantation in CML patients was significantly higher than that of 6-12 months (34.3%, 11/32) and ≥12 months (79.2%, 42/53) (P <0.01). The clinical relapse rates of M bcr / abl positive patients in each time period were 19% (1/5 3), 0 (0/32) and 16.2% (6/37). M bcr / abl and m bcr / abl were positive in 5 of 6 patients with recurrent disease. None of the 17 M bcr / abl-positive mbcr / abl-positive specimens were positive for M bcr / abl-positive specimens in 14 hereditary remission patients 6 months after transplantation. CONCLUSIONS: M bcr / abl is still positive in most patients with CML, and is generally negative within 6 months after transplantation. M bcr / abl positive patients may not relapse after transplantation, and M bcr / abl and m bcr / abl fusion Transcripts may help monitor residual leukemia.